Global Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders (Molecular Diagnostics and Genetics) Global Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders (Molecular Diagnostics and Genetics)

Global Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders (Molecular Diagnostics and Genetics‪)‬

Clinical Chemistry 2007, Dec, 53, 12

    • 2,99 €
    • 2,99 €

Beschreibung des Verlags

Hereditary hemochromatosis (HH) [9] is the main cause of inherited iron overload. When present in a homozygous state, the Cys282Tyr mutation in the hemochromatosis (HFE) [10] gene product is the most common genetic background of HH (1). Ten years after the description of this genotype, further investigations of the disease have revealed considerable heterogeneity. First, other HFE genotypes, including the compound heterozygote encoding the Cys282Tyr and His63Asp mutations, have been associated with an HH phenotype, although individuals with such genotypes accumulate less iron than Cys282Tyr homozygotes (1-3). Other rare private HFE mutations responsible for HH have also been reported. Second, Cys282Tyr homozygotes have been demonstrated to lack full penetrance (4), and some individuals homozygous for the Cys282Tyr mutant remain asymptomatic throughout life. Investigators have also described several other genes that present a phenotype similar to that of HFE-related HH, indicating that hemochromatosis is a multigene disorder. Nowadays, HH is considered an autosomal-recessive inherited disorder with 2 clinical forms, adult and juvenile HH (5, 6), defined according to the age of onset. Juvenile hemochromatosis (JH) is due to a mutation in 1 of 2 genes: HFE2 [hemochromatosis type 2 (juvenile); also known as HJV and encoding hemojuvelin] (7) and, more rarely, HAMP (hepcidin antimicrobial peptide) (8). Adult HH is mainly due to mutation in HFE, and TFR2 (transferrin receptor 2) mutations are rarely found (9). Associations between mutations of different genes leading to modified clinical presentations have been described for some patients. Such findings demonstrate that hemochromatosis can be a multigenic or at least a digenic disease. Indeed, HAMP (10), HFE2 (11), or TFR2 (12) mutations that have been associated with HFE genotypes have been described to aggravate the clinical presentation.

GENRE
Wissenschaft und Natur
ERSCHIENEN
2007
1. Dezember
SPRACHE
EN
Englisch
UMFANG
25
Seiten
VERLAG
American Association for Clinical Chemistry, Inc.
ANBIETERINFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
GRÖSSE
235,2
 kB
Characterization of Publicly Available Lymphoblastoid Cell Lines for Disease-Associated Mutations in 11 Genes (Technical Briefs) Characterization of Publicly Available Lymphoblastoid Cell Lines for Disease-Associated Mutations in 11 Genes (Technical Briefs)
2005
Heterozygosity for the C282Y Mutation in the Hemochromatosis Gene is Associated with Increased Serum Iron, Transferrin Saturation, And Hemoglobin in Young Women: A Protective Role Against Iron Deficiency?(Molecular Diagnostics and Genetics) Heterozygosity for the C282Y Mutation in the Hemochromatosis Gene is Associated with Increased Serum Iron, Transferrin Saturation, And Hemoglobin in Young Women: A Protective Role Against Iron Deficiency?(Molecular Diagnostics and Genetics)
1998
Microarray Technology and Applications in the Arena of Genome-Wide Association. Microarray Technology and Applications in the Arena of Genome-Wide Association.
2008
Challenges in Identifying Genetic Risk Factors for Common Multifactorial Disorders (Commentary) (Report) Challenges in Identifying Genetic Risk Factors for Common Multifactorial Disorders (Commentary) (Report)
2008
Association of Gene Polymorphisms with Development of Cancer Risk Or Their Protective Role Associated with Some Mutant Alleles (Commentary) Association of Gene Polymorphisms with Development of Cancer Risk Or Their Protective Role Associated with Some Mutant Alleles (Commentary)
2011
Mitochondrial Diseases Mitochondrial Diseases
2013
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report) Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report)
2002
Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs) Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs)
2004
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
A Conversation with Elizabeth Blackburn (Interview) A Conversation with Elizabeth Blackburn (Interview)
2009
The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective) The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective)
1998